Researchers are learning more about what makes lung cancer cells form, grow, and spread. Every cell in the body has the same library of genes that acts as the blueprint for everything else that makes up a cell and makes it work. In cancer cells, damage to these genes (mutations) is responsible for the cells becoming cancerous. Some of these mutations create proteins in cells that act like a stuck gas pedal in your car to make it drive out of control. These mutant proteins in cancer cells are good “targets” for new drugs. These drugs are known as TARGETED THERAPIES. Targeted therapies work by blocking these mutant proteins, which prevents them from growing and spreading, while not harming normal cells. Tarceva® (Erlotinib), Gilogrif® (Afatanib), Xalkori® (Crizotinib) and Zykadia® (Ceritinib) are examples of FDA-approved drugs that target the mutated proteins, some of which are referred to as “receptors” that are driving the cancer cells out of control.
Check out LCFA’s Personalized Therapies for Lung Cancer brochure (updated April, 2017) with all of the information contained in this area of our website. We are happy to share this valuable information with you.
Please Note: The information contained in this section of the LCFA website is meant for informational purposes only. It does not replace the advice of a licensed healthcare provider. It is recommended that you consult with a licensed healthcare provider about your diagnosis, treatment and general care.